Literature DB >> 22247440

Meeting the challenges of an emerging pathogen: the Henry Schueler 41&9 Foundation International Forum on Mucormycosis.

Thomas J Walsh1, Bruce E Bloom, Dimitrios P Kontoyiannis.   

Abstract

Invasive mucormycosis comprises a group of uncommon but emerging life-threatening pulmonary, sinal, rhinocerebral, and disseminated infections, which cause debilitating morbidity and severe mortality in our most vulnerable pediatric and adult immunocompromised patients. While important advances are being achieved in understanding the epidemiology, molecular taxonomy, pathogenesis, pharmacology, host defenses, and microbiology of these infections, there are critical needs for improving these approaches for diagnosis, treatment, and prevention. This supplement is dedicated to the memory and courage of Hank Schueler, who fought valiantly against this infection. It provides a comprehensive resource for current approaches to management of this infection and also reviews the key advances against invasive mucormycosis.

Entities:  

Mesh:

Year:  2012        PMID: 22247440     DOI: 10.1093/cid/cir862

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

1.  White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens.

Authors: 
Journal:  Clin Infect Dis       Date:  2012-08-13       Impact factor: 9.079

Review 2.  Update on mucormycosis pathogenesis.

Authors:  Ashraf S Ibrahim; Dimitrios P Kontoyiannis
Journal:  Curr Opin Infect Dis       Date:  2013-12       Impact factor: 4.915

3.  Rhino-orbital-cerebral mucormycosis.

Authors:  Maria N Gamaletsou; Nikolaos V Sipsas; Emmanuel Roilides; Thomas J Walsh
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

4.  Successful treatment of disseminated mucormycosis in a neutropenic patient with T-cell acute lymphoblastic leukaemia.

Authors:  Chelsea Guymer; Sanjeev Khurana; Ram Suppiah; Iain Hennessey; Celia Cooper
Journal:  BMJ Case Rep       Date:  2013-07-31

5.  Development of new strategies for early diagnosis of mucormycosis from bench to bedside.

Authors:  Thomas J Walsh; Anna Skiada; Oliver A Cornely; Emmanuel Roilides; Ashraf Ibrahim; Theoklis Zaoutis; Andreas Groll; Olivier Lortholary; Dimitrios P Kontoyiannis; George Petrikkos
Journal:  Mycoses       Date:  2014-12       Impact factor: 4.377

6.  Successful isavuconazole salvage therapy in a patient with invasive mucormycosis.

Authors:  J Ervens; M Ghannoum; B Graf; S Schwartz
Journal:  Infection       Date:  2013-11-12       Impact factor: 3.553

Review 7.  Host-iron assimilation: pathogenesis and novel therapies of mucormycosis.

Authors:  Ashraf S Ibrahim
Journal:  Mycoses       Date:  2014-09-01       Impact factor: 4.377

8.  Fob1 and Fob2 Proteins Are Virulence Determinants of Rhizopus oryzae via Facilitating Iron Uptake from Ferrioxamine.

Authors:  Mingfu Liu; Lin Lin; Teclegiorgis Gebremariam; Guanpingsheng Luo; Christopher D Skory; Samuel W French; Tsui-Fen Chou; John E Edwards; Ashraf S Ibrahim
Journal:  PLoS Pathog       Date:  2015-05-14       Impact factor: 6.823

9.  Mucormycosis in patients with inflammatory bowel disease: case series and review of the literature.

Authors:  Maheen Z Abidi; Nayantara Coelho-Prabhu; James Hargreaves; Tim Weiland; Irminne Van Dyken; Aaron Tande; Pritish K Tosh; Randall C Walker; Nathan W Cummins
Journal:  Case Rep Med       Date:  2014-04-27

10.  Early Differential Diagnosis of Rhino-Orbito-Cerebral Mucormycosis and Bacterial Orbital Cellulitis: Based on Computed Tomography Findings.

Authors:  Jun Hyuk Son; Hyung Bin Lim; Soo Hyun Lee; Jae Wook Yang; Sung Bok Lee
Journal:  PLoS One       Date:  2016-08-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.